Trial registration
TNBC
TRIPLE-NEGATIVE BREAST CANCER
NCT03853707.More effective therapeutic strategies targeting underlying genomic drivers, as well as novel combinations, are urgently needed for treatment of triple-negative breast cancer (TNBC). This article evaluates the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic TNBC.